Table Of Contents

1. Market Context & Strategic Relevance

 1.1 Opening Context (Why the market matters)

 1.1.1 Why This Market Is Gaining Strategic Attention

     1.1.2 Business Decisions This Report Supports

 1.2 Scope

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Drug Type

  2.3.2 Market Size By Disease Stage

  2.3.3 Market Size By Distribution Channel

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Active Pharmaceutical Ingredients (APIs), Biologic Raw Materials, Chemical Intermediates & Excipient Suppliers

3.4.2 Drug Discovery, Clinical Development, Pharmaceutical Manufacturing, Fill-Finish Operations & Quality Assurance Providers

3.4.3 Pharmaceutical Distributors, Specialty Pharmacy Networks, Cold Chain Logistics & Hospital Supply Channels

3.4.4 Hospitals, Specialty Liver Clinics, Retail & Online Pharmacies, Hepatologists, Gastroenterologists & Patients

 3.5 Industry Life Cycle Assessment

4. Statistical Insights & Trends Reporting

 4.1 Market Adoption & Treatment Trends

4.1.1 NASH Treatment Adoption by Drug Type

4.1.2 Patient Distribution by Disease Stage

4.1.3 Prescription Trends Across Distribution Channels

4.1.4 Treatment Utilization in Advanced Fibrosis Patients

4.1.5 Patient Diagnosis & Therapy Initiation Trends

4.2 Drug Development & Innovation Insights

4.2.1 Clinical Pipeline & Late-Stage Drug Development Analysis

4.2.2 Advances in GLP-1 Receptor Agonists & Combination Therapies

4.2.3 Biomarker-Based Diagnosis & Precision Medicine Trends

4.2.4 Novel Mechanisms of Action in NASH Therapeutics

4.2.5 Regulatory Approvals & Breakthrough Therapy Designations

4.3 Commercial & Industry Intelligence

4.3.1 Drug Pricing & Reimbursement Trends

4.3.2 Competitive Benchmarking of Leading Pharmaceutical Companies

4.3.3 Licensing Agreements, Collaborations & M&A Activity

4.3.4 Distribution Network & Specialty Pharmacy Analysis

4.3.5 Clinical Trial Landscape & Investment Trends

4.4 Future Outlook & Emerging Opportunities

4.4.1 Expansion of Combination Therapy Approaches

4.4.2 Growing Focus on Early-Stage NASH Intervention

4.4.3 Opportunities in Personalized Liver Disease Management

4.4.4 Future Roadmap for Next-Generation NASH Therapeutics

5. Non-alcoholic Steatohepatitis Treatment Market Segmental Analysis & Forecast, By Drug Type, 2022–2035, Value (USD Billion)

5.1 Introduction

 5.2 Vitamin E and Pioglitazone

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.3 Semaglutide

 5.4 Obeticholic Acid

 5.5 Other Pipeline Drugs

6. Non-alcoholic Steatohepatitis Treatment Market Segmental Analysis & Forecast, By Disease Stage, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 NASH Stage F0

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 NASH Stage F1

 6.4 NASH Stage F2

 6.5 NASH Stage F3-F4

7. Non-alcoholic Steatohepatitis Treatment Market Segmental Analysis & Forecast, By Distribution Channel, 2022–2035, Value (USD Billion)

    7.1 Introduction

 7.2 Hospital Pharmacies

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Retail and Specialty Pharmacies

 7.4 Online Pharmacies

8. Non-alcoholic Steatohepatitis Treatment Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)

8.1 Introduction

8.2 North America

 8.2.1 Key Trends

 8.2.2 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Drug Type, 2022–2035

 8.2.3 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Disease Stage, 2022–2035

 8.2.4 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Distribution Channel, 2022–2035

 8.2.5 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Country, 2022–2035

  8.2.5.1 USA

  8.2.5.2 Canada

8.3 Europe

 8.3.1 Key Trends

 8.3.2 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Drug Type, 2022–2035

 8.3.3 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Disease Stage, 2022–2035

 8.3.4 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Distribution Channel, 2022–2035

 8.3.5 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Country, 2022–2035

  8.3.5.1 Germany

  8.3.5.2 UK

  8.3.5.3 France

  8.3.5.4 Italy

  8.3.5.5 Spain

  8.3.5.6 Russia

  8.3.5.7 Poland

  8.3.5.8 Rest of Europe

8.4 Asia-Pacific

 8.4.1 Key Trends

 8.4.2 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Drug Type, 2022–2035

 8.4.3 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Disease Stage, 2022–2035

 8.4.4 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Distribution Channel, 2022–2035

 8.4.5 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Country, 2022–2035

  8.4.5.1 China

  8.4.5.2 India

  8.4.5.3 Japan

  8.4.5.4 South Korea

  8.4.5.5 Australia

  8.4.5.6 ASEAN Countries

  8.4.5.7 Rest of Asia-Pacific

8.5 Latin America

 8.5.1 Key Trends

 8.5.2 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Drug Type, 2022–2035

 8.5.3 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Disease Stage, 2022–2035

 8.5.4 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Distribution Channel, 2022–2035

 8.5.5 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Country, 2022–2035

  8.5.5.1 Brazil

  8.5.5.2 Argentina

  8.5.5.3 Mexico

  8.5.5.4 Colombia

  8.5.5.5 Rest of Latin America

8.6 Middle East & Africa

 8.6.1 Key Trends

 8.6.2 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Drug Type, 2022–2035

 8.6.3 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Disease Stage, 2022–2035

 8.6.4 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Distribution Channel, 2022–2035

 8.6.5 Non-alcoholic Steatohepatitis Treatment Market Size & Forecast, By Country, 2022–2035

  8.6.5.1 UAE

  8.6.5.2 Saudi Arabia

  8.6.5.3 Qatar

  8.6.5.4 Egypt

  8.6.5.5 South Africa

  8.6.5.6 Rest of Middle East & Africa

9. Competitive Landscape

 9.1 Key Players' Positioning

 9.2 Competitive Developments

  9.2.1 Key Strategies Adopted (%), By Key Players, 2025

  9.2.2 Year-Wise Strategies & Development, 2022–2025

  9.2.3 Number Of Strategies Adopted By Key Players, 2025

 9.3 Market Share Analysis, 2025

 9.4 Drug Type/Service & Disease Stage Benchmarking

  9.4.1 Drug Type/Service Specifications & Features By Key Players

  9.4.2 Drug Type/Service Heatmap By Key Players

  9.4.3 Disease Stage Heatmap By Key Players

 9.5 Industry Start-Up & Innovation Landscape

9.6 Key Company Profiles

 9.6.1 Novo Nordisk A/S

  9.6.1.1 Company Overview & Snapshot

  9.6.1.2 Drug Type/Service Portfolio

  9.6.1.3 Key Company Financials

  9.6.1.4 SWOT Analysis

 9.6.2 Intercept Pharmaceuticals, Inc.

9.6.3 Madrigal Pharmaceuticals, Inc.

9.6.4 Gilead Sciences, Inc.

9.6.5 Pfizer Inc.

9.6.6 Boehringer Ingelheim GmbH

9.6.7 Genfit S.A.

9.6.8 Akero Therapeutics, Inc.

9.6.9 Viking Therapeutics, Inc.

9.6.10 89bio, Inc.

9.6.11 Inventiva S.A.

9.6.12 Sagimet Biosciences Inc.

9.6.13 Terns Pharmaceuticals, Inc.

9.6.14 Galmed Pharmaceuticals Ltd.

9.6.15 Zydus Lifesciences Limited

9.6.16 NGM Biopharmaceuticals, Inc.

9.6.17 Bristol-Myers Squibb Company

9.6.18 Eli Lilly and Company

9.6.19 AstraZeneca plc

9.6.20 Alfasigma S.p.A.

10. Analyst Recommendations

 10.1 SNS Insider Opportunity Map

 10.2 Industry Low-Hanging Fruit Assessment

 10.3 Market Entry & Growth Strategy

 10.4 Analyst Viewpoint & Suggestions On Market Growth

11. Assumptions

12. Disclaimer

13. Appendix

 13.1 List Of Tables

 13.2 List Of Figures